Immunomodulating therapy: new treatment modality in congestive heart failure (Q35097101)

6 August 2017

1 reference

title

Immunomodulating therapy: new treatment modality in congestive heart failure (English)

1 reference

6 August 2017

main subject

congestive heart failure

1 reference

2

Jan Kristian Damås

0 references

Pål Aukrust

series ordinal

1

object named as

Pål Aukrust

0 references

Lars Gullestad

series ordinal

3

object named as

Lars Gullestad

1 reference

6 August 2017

publication date

1 March 2003

1 reference

6 August 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Congestive Heart Failure

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

64-69

1 reference

Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

The role of inflammation and infection in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Chlamydia infections and heart disease linked through antigenic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Endotoxin and immune activation in chronic heart failure: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Cyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

The role of oxidative stress in the genesis of heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Requirement of MIP-1 alpha for an inflammatory response to viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Chemokines beyond inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Propranolol treatment affects parameters of human immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

New therapies for heart failure: is thalidomide the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.00682.X

10.1111/J.1527-5299.2003.00682.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference